We previously showed that transient depletion of dividing T cells at the time of an allogeneic transplantation induces long-term tolerance to the allograft. Here we investigated the role of 
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Introduction
Various mechanisms operate during induction and maintenance of transplantation tolerance.
Recessive processes such as T-cell deletion or anergy can reduce effector functions against allogeneic donor cells but are not always sufficient. Consequently, dominant processes mediated by regulatory T cells (Treg) are important to establish natural and transplantation tolerance (1) (2) (3) (4) . Treg can be selected centrally in the thymus and can also be selected in the periphery. In the thymus, epithelial cells play an essential role in the positive selection of specific CD4 + regulatory T cells that are able to induce transplantation tolerance (4) (5) (6) . In the periphery, dominant transplantation tolerance can be obtained through different methods that result in the emergence of Treg. These methods include (i) costimulatory blockade (7) (8) (9) (10) (11) ; (ii) non-depleting anti-CD4 therapy (11-13) associated or not with donor specific blood transfusion (14) ; and (iii) induction of tolerogenic dendritic cells by various protocols including treatment with vitamin D receptor ligands (15) , opsonization of apoptotic cells and capture of antigens by immature or plasmacytoid dendritic cells (16, 17) . Induction of peripheral tolerance can also be triggered by experimental protocols that result either in clonal deletion or inactivation of T cells, associated with expansion of Treg (18, 19) . Depletion of alloreactive T cells by apoptosis, leading to the emergence of Treg, was suggested to be a requirement for transplantation tolerance induction (20) . However, T-cell depletion can also trigger homeostatic proliferation of memory T cells, which can impair the induction of transplantation tolerance (21) . Thus, a therapeutic strategy that can destroy alloreactive T cells by apoptosis, including memory T cells, but preserve quiescent T cells and induce the emergence of Treg would be valuable for allograft tolerance induction.
We previously described a strategy by which long-term tolerance to surgically vascularized heart allograft was induced in mice. Our treatment was based on a time-controlled, selective destruction of dividing T cells for two weeks, starting at the time of transplantation, thus mainly targeting alloreactive T cells. This was achieved by the pharmacogenetic depletion of dividing T cells expressing the therapeutic conditional suicide gene, thymidine kinase of type 1 Herpes Simplex Virus (HSV1-TK). HSV1-TK phosphorylates the inactive prodrug ganciclovir (GCV), changing it into a toxic triphosphorylated-GCV nucleotide analog. This analog, when incorporated into a growing DNA strand, blocks its elongation and leads to apoptosis of the dividing cells. We previously generated transgenic mice specifically expressing the HSV1-TK suicide gene in both CD4 Using these mice, we showed that the transient depletion of dividing T cells by GCV (i) controls T-cell mediated immune diseases involving alloreactive and pathogenic T cells (22) (23) (24) (25) (26) ; (ii) induces long-term, specific, and robust tolerance to vascularized allogeneic heart grafts (27) or delayed rejection of self-vascularized skin and heart (28); (iii) and disrupts immunological memory maintenance (29) . Here we show, in allogeneic pancreatic islet transplantation, that tolerance induction is mediated by a progressive expansion of Treg. This expansion is a direct consequence of an altered homeostatic balance following the depletion of dividing T cells by apoptosis. 
Materials and Methods

Mice
GCV and hydroxyurea (HU) administration
The modality of the GCV (Cymevan, Roche, France) administration was previously studied in vitro and in vivo (28) . GCV was diluted in pyrogen-free H 2 O, filtered (0.22µm) and administered by mini-osmotic pumps (Alzet 2001 or 2002, Charles River Laboratories), which delivered GCV at the dose of 50 mg/kg/day for 7 or 14 days allowing a plasma concentration of 7.4 µM. Pumps were implanted s.c. under ketamine (150 mg/kg) and xylazine (10 mg/kg i.p.) anesthesia at the time of transplantation. HU (Hydrea, Bristol-Myers Squibb) was administrated as cycle of 2 ip injections at 1g/kg/day, 7 hours apart; mice received 6 cycles every 2 or 3 days over a 12 days period.
Islet isolation
Islets were isolated as previously described (31) by stationary digestion with Liberase RI (Roche diagnostics, Meylan, France) after in situ distension of the pancreas. Islets were purified on a discontinuous Euroficoll gradient, handpicked to obtain 100% purity and cultured overnight at 37 °C and 5% CO 2 before transplantation.
Islet transplantation and follow-up
Recipients were rendered diabetic by a single intraperitoneal injection of streptozotocin (STZ, Sigma-Aldrich, France) and 1000 islets were grafted under the left kidney capsule as previously described (31) . The experimental group consisted of TK Blood glucose concentrations (glycemia) were measured using a glucometer (kindly provided by Bayer Diagnostic, France). Rejection was defined as the observance of two successive non-fasting blood glucose concentrations > 200 mg/dl. Mice that did not become hyperglycemic after removal of the graft-bearing kidney were excluded from the study because regeneration of the native endogenous endocrine pancreatic function had occurred, making clinical assessment of the graft function impossible.
Graft infiltrating cells
For immunohistological analysis, 8 µm cryostat sections of the islet-bearing kidney were stained as previously described (32) . Briefly, we used biotinylated anti-CD4/CD8 mAbs followed by the enzymatic avidin-biotin-peroxidase/ 3-amino -9-ethyl carbazole reaction and H/E staining. We observed the slides on a Nikon DIAPHOT microscope (Nikon, France SA).
To obtain cell suspensions for FACS analysis, islets were separated from the kidney and digested with 1.6 mg/ml type IV collagenase (Sigma Aldrich, France) and 200 µg/ml DNase I at 37 °C for 30 minutes.
Skin grafts
Skin pieces (1cm 2 ) from tail mouse were grafted on the back of recipients under ketamine (150 mg/kg) and xylazine (10 mg/kg i.p.) anesthesia and follow up was done as previously described (28) .
Cell suspensions
Spleen cell suspensions and pooled axillary, brachial and inguinal lymph node cell suspensions were obtained by mechanical dilacerations. Live cells were counted after trypan blue exclusion. PBL were separated by gradient density on MSL (Eurobio Biotechnology).
Lymphocyte proliferation and cytotoxicity
Cells were cultured for 3 days at 37 °C with 5% CO 2 in RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine, 5x10 ) target cells was assayed as described (29) .
Tolerance transfer experiments
Secondary recipients were made diabetic by STZ injection, then sublethally irradiated (2 Gy).
The next day, splenocytes were harvested from primary tolerant recipients. The cell suspension was injected i.v. into the retro-orbital sinus of the secondary recipients at the time of islet allograft transplantation under the kidney capsule.
In vivo treatment with anti-CD25 mAb
Mice received one i.p.injection of 100µg in 100µl of PC61 IgG1 anti-CD25 monoclonal antibody.
Immunostaining and flow cytometry
Cells (2x10 These results show that a state of long-term tolerance was achieved in at least 60% of the mice.
Tolerant recipient splenocytes retain normal proliferative and CTL functions in vitro
To address the mechanisms of tolerance -deletion, anergy or suppression -we assayed the proliferative and cytotoxic capacities of T cells from grafted recipients. Two to three months 
In vivo specificity of the tolerance
We further assessed the immunocompetence and the antigen specificity of tolerance by the ability of TK + GCV + tolerant mice to reject a third party skin or islet allograft When mice tolerant to B6 islets for more than 2 months, received skin grafts without treatment ( Figure   3A ), the BALB/c third party skin was acutely rejected in 17 days as in naïve recipients (p>0.05 Logrank test) while the B6 skin rejection was chronic and delayed to 31 days (p<0.05
Logrank test compared to BALB/c graft and compared to rejection of B6 skin in naïve recipient). A second islet of third-party origin (BALB/c) grafted on day 42 on a tolerant mouse was rejected in less than 29 days (not shown). Thus, tolerance is specific of B6 donor haplotype but not of islet since skin graft survival was prolonged.
In vivo suppression of islet graft rejection by adoptive transfer of splenocytes from tolerant mice
We analyzed whether splenocytes from TK + GCV + tolerant mice could suppress rejection of allogeneic islet graft upon transfer to normal immunocompetent mice rendered diabetic.
Recipient mice, were sublethally (2Gy) irradiated before cell transfer to favor T-cell engraftment; this conditioning did not alter the capacity of mice to reject islet allografts, which occurred in 22 ± 1 days ( Figure 3C (Fig.4E, 6D ). This is in accordance with their insensibility to T cell depletion and activation/expansion of effector T cells.
Homeostatic imbalance following transient T cell depletion
We investigated whether emergence of Treg is related to homeostatic imbalance following the initial depletion of dividing T cells. We compared the T-cell dynamics of TK 
Persistence of tolerance and Treg cells after depletion of CD25 T cells
In order to address directly if CD25 T cells are responsible of the tolerant state, we treated tolerant mice (on day 60 after B6 islet graft) with PC61 monoclonal antibody reported to induce depletion of CD25 T cells in vivo. Mice remained normoglycemic until day 74 where removal of the graft induces hyperglycemia (Fig.5A) . The kinetics of Treg cells in blood before and after PC61 treatment (Fig.5B-C) 
Transient depletion of dividing T cells by Hydroxyurea induce tolerance
We also investigated whether the transient depletion (Fig.6 D) .
Discussion
In this study, the induction of dominant tolerance to islet allografts was obtained through transitory depletion of dividing T cells at the time of transplantation, leading to emergence of Treg cells. Using self-vascularized islet grafts we confirm and extend our previous findings using surgically-vascularized heart allografts (27) . The different success rates for tolerance induction differed for self-vascularized heart or skin (0% tolerant, delayed rejection only) (28) , islet allografts (63% tolerant), and vascularized heart (84% tolerant) (27, 34) . Of interest, percentage of tolerance correlate well with the frequency of T cells triggered to divide, depending on the nature of the graft. Indeed, Jones et al. reported that 14%, 19%, 44%, and of T cells have undergone at least one cell division seven days after skin, islet, and vascularized-heart allografts respectively (35) . Thus, allografts that induce a large number of T-cell divisions might be more easily tolerated following a dividing-T-cell depletion protocol, than allografts that induce a smaller number of divisions.
The initial clonal deletion of dividing T cells, including donor-specific T cells is of importance to decrease the size of the cytopathic T-cell compartment (27, 28) . Nevertheless, there is no long-term clonal deletion or anergy of effector T cells, nor generalized immunodeficiency and recent thymic emigrants can renew the T-cell compartment and donorspecific T cells. In long-term tolerant mice, although the total number of T lymphocytes was reduced by 30% compared to naïve mice, the immunocompetence was not qualitatively altered in vivo or in vitro. Thus, tolerant mice (i) rejected a third party skin or islet allograft,
(ii) maintained proliferative T-cell responses to mitogen, donor and third party antigens, and (iii) maintained donor-specific cytotoxic activities and IFNγ production. The fact that in vitro assays of proliferation were done with constant numbers of splenic cells, containing 30% less The dissociation between in vitro reactivity and in vivo tolerance, also called "split tolerance", has been described in various models of tolerance and extensively discussed (36, 37) . In vitro reactivity is tested against hematopoeitic cells of donor haplotype, far for physiological conditions. This differs from the in vivo context, where the local concentration and activation of regulatory T cells in graft achieve tissue-specific control of graft rejection, as also previously reported (5, 38) . In B6-islet tolerant mice, the B6 skin graft survival was only prolonged (MST 31 days) as compared with third party skin. Of note a similar prolongation of B6 skin graft survival (MST 39 days) was previously observed in TK + GCV + mice (28) . This suggests that the B6 islet allograft could induce a "partial" tolerance to skin of the same H-2 b haplotype, which is nevertheless per se difficult to tolerize in this model. However, the transfer of splenocytes from B6 islet tolerant mice, while controlling B6 islet rejection in 40% of recipient mice, does not control B6 skin rejection, suggesting that tolerance is dominant, tissue specific and requires a minimal number of tissue specific Treg cells to be achieved (5).
As in other models (7, (39) (40) (41) (Fig. 4 and (28) ), which essentially reflects the natural Tcell renewal rate (43) (46) or to induce rejection via proliferation of memory cells (21) . As observed here, homeostatic expansion of regulatory T cells can also take place during the lymphopenic phase of immuno-reconstitution in patients treated for autoimmunity (47) , or after T cell depletion via anti-CD52 Ab and rapamycin inducing human renal transplantation tolerance (48) After the third week, in non-grafted mice thymic export and homeostatic proliferation ( Figure   4 and (43) (52), favoring the emergence of Treg (53, 54) . This is in accordance with the observation that inhibition of dendritic cell maturation by treatment with an active form of vitamin D3 leads to tolerance to both islet and vascularized heart allografts (15).
Depletion of dividing T cells avoids the drawbacks of other models (21, 55) since it decreases
the size of the cytopathic donor alloreactive T-cell compartment, but it also targets dividing "memory" T cells turning a typical "2d set" rejection kinetics of a second skin allograft into a primary ones, using GCV in TK + recipient or HU treatment (29) . Thus, this type of approach could be of interest to control rejection of allograft in naïve but also in allo-sensitized recipients.
Our study is the first to demonstrate that specific and transient depletion of dividing T cells at the time of transplantation is sufficient to alter the homeostatic balance between effector and regulatory T cells and to establish a dominant transferable tolerance to islet allografts. While pharmacogenetic T cell depletion would be difficult to implement in humans, it opens the way for using drugs that induce apoptosis of dividing T cells and mimic the effects of TK/GCV treatment. As shown here, Hydroxyurea is a potent candidate, since tolerance favoring Treg 
